- Ultragenyx Pharmaceutical (RARE) said that new long-term data for its AAV9 gene therapy for Sanfilippo syndrome Type A, UX111 (rebisufligene etisparvovec), indicated durable biomarker improvements and functional benefits.
- The data showed that in children under two years old at the